196 related articles for article (PubMed ID: 12575830)
1. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins.
Pardridge WM
Adv Exp Med Biol; 2002; 513():397-430. PubMed ID: 12575830
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in experimental stroke with targeted neurotrophins.
Wu D
NeuroRx; 2005 Jan; 2(1):120-8. PubMed ID: 15717063
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin.
Zhang Y; Pardridge WM
Brain Res; 2001 Jan; 889(1-2):49-56. PubMed ID: 11166685
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
Zhang Y; Pardridge WM
Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502
[TBL] [Abstract][Full Text] [Related]
5. Neurotrophins, neuroprotection and the blood-brain barrier.
Pardridge WM
Curr Opin Investig Drugs; 2002 Dec; 3(12):1753-7. PubMed ID: 12528312
[TBL] [Abstract][Full Text] [Related]
6. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection with noninvasive neurotrophin delivery to the brain.
Wu D; Pardridge WM
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):254-9. PubMed ID: 9874805
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
9. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector.
Song BW; Vinters HV; Wu D; Pardridge WM
J Pharmacol Exp Ther; 2002 May; 301(2):605-10. PubMed ID: 11961063
[TBL] [Abstract][Full Text] [Related]
10. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
11. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
13. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
Pardridge WM
BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
[TBL] [Abstract][Full Text] [Related]
14. Brain drug targeting and gene technologies.
Pardridge WM
Jpn J Pharmacol; 2001 Oct; 87(2):97-103. PubMed ID: 11700018
[TBL] [Abstract][Full Text] [Related]
15. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice.
Kilic U; Kilic E; Dietz GP; Bähr M
Stroke; 2003 May; 34(5):1304-10. PubMed ID: 12677018
[TBL] [Abstract][Full Text] [Related]
16. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
17. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.
Pardridge WM; Wu D; Sakane T
Pharm Res; 1998 Apr; 15(4):576-82. PubMed ID: 9587954
[TBL] [Abstract][Full Text] [Related]
18. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.
Pardridge WM; Kang YS; Buciak JL
Pharm Res; 1994 May; 11(5):738-46. PubMed ID: 8058646
[TBL] [Abstract][Full Text] [Related]
19. Drug targeting to the brain.
Pardridge WM
Pharm Res; 2007 Sep; 24(9):1733-44. PubMed ID: 17554607
[TBL] [Abstract][Full Text] [Related]
20. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
Pardridge WM
Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
